Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAR001 in hypertriglyceridemia
NCT07199309Phase 2Recruiting
- Sponsor
- Marea Therapeutics
- Start
- Sep 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of MAR001 in hypertriglyceridemia, sponsored by Marea Therapeutics. Started Sep 2025; status: recruiting.
02
Drugs
MAR001
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT07199309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199309.